Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous mesenchymal stem cells (Fondazione IRCCS Ca' Granda)
- Development stage
- Unknown
- Lead developer
- IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial
01
Overview
This experimental autologous mesenchymal stem cell (MSC) therapy is an Advanced Therapy Medicinal Product (ATMP) developed by Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico for the treatment of Progressive Supranuclear Palsy (PSP). The therapy involves harvesting mesenchymal stromal cells from a patient's own bone marrow, expanding them under Good Manufacturing Practice (GMP) conditions in the hospital's Cell Factory, and administering them via intra-arterial infusion through the internal carotid arteries. The mechanism of action is hypothesized to involve the secretion of neurotrophic factors, anti-apoptotic signals, and anti-inflammatory cytokines that support surviving neurons and modulate the neurodegenerative environment. A Phase 1 clinical trial (NCT01824121) evaluated the safety and preliminary efficacy of this approach, utilizing a randomized, double-blind, sham-controlled crossover design.
- Other names
- autologous mesenchymal stem cell therapybone marrow-derived mesenchymal stem cells
Beyond the preview
Go deeper on autologous mesenchymal stem cells (Fondazione IRCCS Ca' Granda).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous mesenchymal stem cells (Fondazione IRCCS Ca' Granda).